You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Impact of RNA signatures on pCR and survival after 12-week neoadjuvant pertuzumab plus trastuzumab with or without paclitaxel in the WSG-ADAPT-HER2+/HR- trial
|
|---|---|
| Published in |
Clinical Cancer Research, November 2022
|
| DOI | 10.1158/1078-0432.ccr-22-1587 |
| Pubmed ID | |
| Authors |
Monika Graeser, Oleg Gluz, Claudia Biehl, Daniel Ulbrich-Gebauer, Matthias Christgen, Jenci Palatty, Sherko Kuemmel, Eva-Maria Grischke, Doris Augustin, Michael Braun, Jochem Potenberg, Rachel Wuerstlein, Katja Krauss, Claudia Schumacher, Helmut Forstbauer, Toralf Reimer, Andrea Stefek, Hans Holger. Fischer, Enrico Pelz, Christine zu Eulenburg, Ronald Kates, Hua Ni, Cornelia Kolberg-Liedtke, Friedrich Feuerhake, Hans Heinrich. Kreipe, Ulrike Nitz, Nadia Harbeck |
| Abstract |
TTo identify associations of biological signatures and stromal tumor infiltrating lymphocytes (sTILs) with pathological complete response (pCR, ypT0 ypN0) and survival in the phase II WSG-ADAPT HER2+/HR- trial (NCT01817452). Patients with cT1-cT4c, cN0-3 HER2+/HR- early breast cancer (EBC) were randomized to pertuzumab+trastuzumab (P+T, n=92) or P+T+paclitaxel (n=42). Gene expression signatures were analyzed in baseline (BL) biopsies using NanoString Breast Cancer 360 panel (n=117); BL and on-treatment (week 3) sTIL levels were available in 119 and 76 patients, respectively. Impacts of standardized gene expression signatures on pCR and invasive disease-free survival (iDFS) were estimated by logistic and Cox regression. In all patients, ERBB2 (OR 1.70; 95%CI 1.08-2.67) and estrogen receptor (ER) pathway signaling signatures (OR 1.72; 95%CI 1.13-2.61) were favorable, while PTENsignature (OR 0.57; 95%CI 0.38-0.87) was unfavorable for pCR. After 60 months median follow-up, 13 invasive events occurred (P+T: n=11, P+T+paclitaxel: n=2), none following pCR. Gene signatures related to immune response (IR) and ER signaling were favorable for iDFS, all with similar HR about 0.43-0.55. These patterns were even more prominent in the neoadjuvant chemotherapy-free group, where additionally BRCAness signature was unfavorable (HR 2.00; 95%CI 1.04-3.84). IR signatures were strongly intercorrelated. sTILs (BL/week 3/change) were not associated with pCR or iDFS, though BL-sTILs correlated positively with IR signatures. Distinct gene signatures were associated with pCR vs iDFS in HER2+/HR- EBC. The potential role of IR in preventing recurrence suggests that patients with up-regulated IR signatures could be candidates for de-escalation concepts in HER2+ EBC. |
X Demographics
The data shown below were collected from the profiles of 13 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 15% |
| United States | 2 | 15% |
| Mexico | 1 | 8% |
| Portugal | 1 | 8% |
| Brazil | 1 | 8% |
| Italy | 1 | 8% |
| Unknown | 5 | 38% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 6 | 46% |
| Members of the public | 4 | 31% |
| Scientists | 3 | 23% |
Mendeley readers
The data shown below were compiled from readership statistics for 13 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 13 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 5 | 38% |
| Student > Bachelor | 2 | 15% |
| Researcher | 1 | 8% |
| Unknown | 5 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 6 | 46% |
| Nursing and Health Professions | 1 | 8% |
| Unknown | 6 | 46% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 November 2022.
All research outputs
#4,464,758
of 25,171,799 outputs
Outputs from Clinical Cancer Research
#4,032
of 13,189 outputs
Outputs of similar age
#90,609
of 487,906 outputs
Outputs of similar age from Clinical Cancer Research
#57
of 112 outputs
Altmetric has tracked 25,171,799 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,189 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.7. This one has gotten more attention than average, scoring higher than 69% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 487,906 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 112 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.